Listing of Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Claims

(previously presented)
A method of treating urinary incontinence comprising administration of an effective amount of a compound selected from one of the Formulae IA, IB, IIA, IIB, IIIA or IIIB

wherein

 R^1 is selected from the group consisting of C_rC_6 alkyl, C_2rC_6 alkenyl, C_2rC_6 alkynyl, C_3rC_6 cycloalkyl, C_4rC_7 cycloalkyl and benzyl, each of which is optionally substituted with 1 to 3 substituents independently selected at each occurrence from C_rC_3 alkyl, halogen, -CN, $-OR^8$ and $-NR^8R^9$:

 R^2 is selected from the group consisting of H, C_rC_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_8 alkynyl, C_3 - C_8 cycloalkyl, C_4 - C_7 cycloalkylalkyl and C_rC_8 haloalkyl;

R³ is selected from the group consisting of H, halogen, C_rC₆ alkyl, C_rC₅ haloalkyl and C₃-C₆ cycloalkyl, wherein C_r-C₆ alkyl, C_r-C₆ haloalkyl and C₃-C₆ cycloalkyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from OR⁸ and NR⁸R⁹;

 $R^4,\,R^9,\,$ and R^6 are each independently selected at each occurrence thereof from the group consisting of H, halogen, $-OR^{10},\,-ND_2,\,-NR^{10}R^{11},\,-NR^{10}C(0)R^{11},\,-RR^{10}C(0)R^{11},\,-RR^{10},\,-RR^{11},\,-RR^{10}C(0)R^{11},\,-RR^{11},\,-RR^{10}C(0)R^{11},\,-RR^{11},\,-RR^{11},\,-RR^{10}C(0)R^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11},\,-RR^{11}$

alternatively R5 and R6 taken together are -0-C(R11)2-0-;

R⁷ is selected from the group consisting of H, halogen and OR¹⁰;

 R^{9} and R^{9} are each independently selected from the group consisting of H, $C_{\Gamma}C_{4}$ alkyl, $C_{\Gamma}C_{4}$ haloalkyl, $C_{\Gamma}C_{4}$ alkoxyalkyl, $C_{\Gamma}C_{4}$ alkoxyalkylalkyl, C_{3} - C_{6} cycloalkyl, C_{4} - C_{7} cycloalkylalkyl, - C(0) R^{12} , phenyl and benzyl, wherein phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from halogen, cyano, $C_{\Gamma}C_{4}$ alkyl, $C_{\Gamma}C_{4}$ haloalkyl, $C_{\Gamma}C_{4}$ alkoxy and $C_{\Gamma}C_{4}$ haloalkoxy, or R^{8} and R^{9} are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, piperazine, N-methyloiperazine, morpholine, or thiomorpholine ring:

 R^{10} is selected from the group consisting of H, C_rC_4 alkyl, C_rC_4 haloalkyl, C_rC_4 alkoxyalkyl, C_3 - C_6 cycloalkyl, C_4 - C_7 cycloalkylalkyl, - $C(O)R^{12}$, phenyl and benzyl, wherein phenyl and benzyl are optionally substituted with 1 to 3 substituents selected. Independently at each

occurrence from halogen, -NH₂, -OH, cyano, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 alkoxy and C_1 - C_4 haloalkoxy;

R¹¹ is selected from the group consisting of H, C_TC₄ alkyl, C_TC₄ haloalkyl, C_TC₄ alkoxyalkyl, C₃-C₆ cycloalkyl, C₄-C₇ cycloalkylalkyl, phenyl and benzyl, where phenyl and benzyl are optionally substituted with 1 to 3 substituents selected independently at each occurrence from halogen, -NH₂, -OH, cyano, C_TC₄ alkyl, C_TC₄ haloalkyl, C_TC₄ alkoxy and C_TC₄ haloalkoxy, or R¹⁰ and R¹¹ are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, N-methylpiperazine, morpholine, or thiomorpholine ring, with the proviso that only one of R⁸ and R9 or R¹⁰ and R¹¹ are taken together with the nitrogen to which they are attached to form a piperidine, pyrrolidine, piperaine, N-methylpiperazine, morpholine, or thiomorpholine ring;

R¹² is selected from the group consisting of C_I-C₄ alkyl, C_I-C₄ haloalkyl and phenyl;

X is selected from the group consisting of 0, NR¹³ and S;

the ring containing X is selected from furan, pyrrole, thiophene, dihydrofuran, dihydropyrrole, and dihydrothiophene; n is 0, 1, or 2; and,

 R^{13} is selected from the group consisting of H, $C_{\Gamma}C_{\delta}$ alkyl, benzyl and phenyl, wherein $C_{\Gamma}C_{\delta}$ alkyl, benzyl and phenyl are optionally substituted with 1-3 substituents independently at each occurrence from halogen, -NH₂, -OH, cyano, $C_{\Gamma}C_{4}$ alkyl, $C_{\Gamma}C_{4}$ haloalkyl, $C_{\Gamma}C_{4}$ alkoxy and $C_{\Gamma}C_{4}$ haloalkoxy;

or a pharmaceutically acceptable salt thereof or an isomer or prodrug thereof to a patient in need thereof.

- 2. (Original) A method of claim 1, wherein R1 is C_I-C₆ alkyl.
- 3. (Original) A method of claim 2, wherein R1 is CH3.
- 4. (Original) A method of claim 1, wherein R^2 is H, C_rC_6 alkyl, C_3-C_6 cycloalkyl, or C_rC_6 haloalkyl.
- (Original) A method of claim 4, wherein R² is H or C_rC₆ alkyl.
- 6. (Original) A method of claim 5, wherein R² is H. PC27831A US Amend & Response DRAFT.doc

- 7. (Original) A method of claim 1, wherein R³ is at each occurrence thereof independently H, halogen, C_I-C₆ alkyl, or C_I-C₆ alkyl substituted with from 1 to 3 of OR® or NR®R°.
- (Original) A method of claim 7, wherein R³ is H or C_I-C₆ alkyl.
- 9. (Original) A method of claim 8, wherein R3 is H.
- 10. (Original) A method of claim 1, wherein R1 is CH3, R2 is H and R3 is H.
- 11. (Original) A method of claim 1, wherein R^4 , R^5 and R^6 are each independently H, halogen, $C_1 \cdot C_6$ alkyl or $-OR^{10}$.
- 12. (Original) A method of claim 11, wherein at least one of R4, R5 and R6 is H.
- 13. (Original) A method of claim 12, wherein each of R4, R5 and R6 are H.
- 14. (Original) A method of claim 12, wherein one of R⁴, R⁵ and R⁶ is halogen.
- 15. (Original) A method of claim 1, wherein R^1 is CH_3 , R^2 and R^3 are each H, and at least one of R^4 , R^5 , and R^6 is H.
- 16. (Original) A method of claim 1 wherein the compound is a compound of Formula (10):

- a compound of Formula (10) wherein R4 is H, R5 is H and R6 is H;
- a compound of Formula (10) wherein R4 is H, R5 is Me and R6 is H;

a compound of Formula (10) wherein R^4 is CI, R^5 is H and R^6 is H; and a compound of Formula (10) wherein R^4 is H. R^5 is F and R^5 is H.

17. (Original) A method of claim 1 wherein the compound is a compound of Formula (20):

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (20) wherein R⁴ is H, R⁵ is H and R⁶ is H:
 - a compound of Formula (20) wherein R4 is H, R5 is Me and R6 is H;
 - a compound of Formula (20) wherein R⁴ is H, R⁵ is Cl and R⁸ is H;
 - a compound of Formula (20) wherein R4 is H. R5 is F and R6 is H: and
 - a compound of Formula (20) wherein R⁴ is F, R⁵ is H and R⁶ is F.

18. (Original) A method of claim 1 wherein the compound is a compound of Formula (30):

- a compound of Formula (30) wherein R³ is H, R⁴ is H, R⁵ is H and R⁶ is H;
- a compound of Formula (30) wherein R³ is H, R⁴ is F, R⁵ is F and R⁶ is H;
- a compound of Formula (30) wherein R3 is H, R4 is F, R5 is H and R6 is F:

a compound of Formula (30) wherein R^3 is H, R^4 is H, R^5 is F and R^6 is H; a compound of Formula (30) wherein R^3 is H, R^4 is Cl, R^5 is H and R^6 is H; a compound of Formula (30) wherein R^3 is H, R^4 is H, R^5 is Cl and R^6 is H; a compound of Formula (30) wherein R^3 is H, R^4 is H, R^5 is Cl and R^6 is F; a compound of Formula (30) wherein R^3 is H, R^4 is H, R^5 is F and R^6 is Cl; a compound of Formula (30) wherein R^3 is H, R^4 is H, R^5 is OMe and R^6 is H; and a compound of Formula (30) wherein R^3 is H, R^4 is H, R^5 is OMe and R^6 is H; and a compound of Formula (30) wherein R^3 is H, R^4 is F, R^5 is H and R^6 is H.

19. (Original) A method of claim 1 wherein the compound is a compound of Formula (40):

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (40) wherein R³ is H, R⁴ is H, R⁵ is H and R⁶ is H; a compound of Formula (40) wherein R³ is H, R⁴ is F, R⁵ is F and R⁶ is H; a compound of Formula (40) wherein R³ is H, R⁴ is F, R⁵ is H and R⁶ is F; a compound of Formula (40) wherein R³ is H, R⁴ is F, R⁶ is H and R⁶ is H; a compound of Formula (40) wherein R³ is H, R⁴ is H, R⁶ is F and R⁶ is H; a compound of Formula (40) wherein R³ is H, R⁴ is H, R⁶ is Cl and R⁶ is H; a compound of Formula (40) wherein R³ is H, R⁴ is H, R⁶ is Cl and R⁶ is H; a compound of Formula (40) wherein R³ is H, R⁴ is H, R⁶ is Cl and R⁶ is F; a compound of Formula (40) wherein R³ is H, R⁴ is H, R⁶ is F and R՞ is Cl; a compound of Formula (40) wherein R³ is H, R⁴ is F, R⁶ is H and R⁶ is Cl; a compound of Formula (40) wherein R³ is H, R⁶ is H and R՞ is Cl; a compound of Formula (40) wherein R³ is H, R⁶ is H and R՞ is H; a compound of Formula (40) wherein R³ is H, R⁶ is H, R⁶ is H and R՞ is H; a compound of Formula (40) wherein R³ is Et, R՞ is H, R՞ is H and R՞ is H; a compound of Formula (40) wherein R³ is Et, R՞ is H, R՞ is H and R՞ is H; a compound of Formula (40) wherein R³ is Et, R՞ is H, R՞ is H and R՞ is H; a compound of Formula (40) wherein R³ is Et, R՞ is H, R՞ is H and R՞ is H; and a compound of Formula (40) wherein R³ is Et, Rổ is H, R՞ is H and Rổ is H; R€ R\$ is H and Rổ is H; and a compound of Formula (40) wherein R³ is CH₂OH, Rổ is H, Rኞ is H and Rổ is H.

20. (Original) A method of claim 1 wherein the compound is a compound of Formula (50):

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (50) wherein R3 is H, R4 is H, R5 is H and R6 is H.

21. (Original) A method of claim 1 wherein the compound is a compound of Formula (60):

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (60) wherein R^3 is H, R^4 is H, R^5 is H, R^6 is H and R^{13} is H; a compound of Formula (60) wherein R^3 is H, R^4 is H, R^5 is H, R^6 is H and R^{13} is H; a compound of Formula (60) wherein R^3 is H, R^4 is H, R^5 is H, R^6 is H and R^{13} is H; a compound of Formula (60) wherein R^3 is H, R^4 is H, R^5 is H, H^6 is H and H^{13} is H; a compound of Formula (60) wherein H^3 is H, H^4 is H, H^6 is H, H^8 is H, H^8 is H, H^8 is H, H^8 is H.

a compound of Formula (60) wherein R3 is H, R4 is Cl. R5 is H, R6 is H and R13 is H; a compound of Formula (60) wherein R3 is H, R4 is Cl, R5 is H, R6 is H and R13 is Me: a compound of Formula (60) wherein R3 is H, R4 is F, R5 is H, R5 is H and R13 is H; a compound of Formula (60) wherein R3 is H, R4 is H, R5 is F, R6 is H and R13 is H: a compound of Formula (60) wherein R3 is H, R4 is F, R5 is Cl, R5 is H and R13 is H: a compound of Formula (60) wherein R3 is H, R4 is F, R5 is Cl, R6 is H and R13 is Me; a compound of Formula (60) wherein R3 is H, R4 is Cl, R5 is F, R6 is H and R13 is H;

and

a compound of Formula (60) wherein R3 is H. R4 is Cl. R5 is F. R6 is H and R13 is Me.

22. (Original) A method of claim 1 wherein the compound is a compound of Formula (70):

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (70) wherein R3 is H, R4 is H. R5 is H. R6 is H and R13 is H: a compound of Formula (70) wherein R3 is H, R4 is H, R5 is H, R6 is H and R13 is Me: a compound of Formula (70) wherein R3 is H. R4 is H. R5 is H. R6 is H and R13 is Et: a compound of Formula (70) wherein R3 is H. R4 is H. R5 is H. R6 is H and R13 is Bn: a compound of Formula (70) wherein R3 is H. R4 is H. R5 is F. R6 is F and R13 is H: a compound of Formula (70) wherein R3 is H, R4 is H, R5 is F, R6 is F and R13 is Me: a compound of Formula (70) wherein R3 is H. R4 is F. R5 is H. R6 is F and R13 is Me: a compound of Formula (70) wherein R3 is H, R4 is CI, R5 is H, R6 is H and R13 is H: a compound of Formula (70) wherein R3 is H, R4 is Cl. R5 is H, R6 is H and R13 is Me: a compound of Formula (70) wherein R3 is H, R4 is F, R5 is H, R6 is H and R13 is H: a compound of Formula (70) wherein R3 is H, R4 is F, R5 is H, R6 is H and R13 is Me: a compound of Formula (70) wherein R3 is H. R4 is H. R5 is F. R6 is H and R13 is H: a compound of Formula (70) wherein R3 is H, R4 is F, R5 is Cl. R6 is H and R13 is H: PC27831A US Amend & Response DRAFT.doc

a compound of Formula (70) wherein R^3 is H, R^4 is F, R^5 is Cl, R^6 is H and R^{13} is Me; a compound of Formula (70) wherein R^3 is H, R^4 is Cl, R^5 is F, R^6 is H and R^{13} is H;

a compound of Formula (70) wherein R3 is H, R4 is Cl, R5 is F, R6 is H and R13 is Me.

23. (Original) A method of claim 1 wherein the compound is a compound of Formula (80):

(80)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (80) wherein R4 is H, R5 is H and R6 is H;

a compound of Formula (80) wherein R4 is H, R5 is F and R6 is H; and

a compound of Formula (80) wherein R4 is H. R5 is F and R6 is F.

24. (Original) A method of claim 1 wherein the compound is a compound of Formula (90):

(90)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (90) wherein R4 is H, R5 is H and R8 is H;

a compound of Formula (90) wherein R4 is H, R5 is F and R6 is F; and

a compound of Formula (90) wherein R4 is H, R5 is F and R6 is H.

and

25. (Original) A method of claim 1 wherein the compound is a compound of Formula (100):

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (100) wherein R⁴ is H, R⁵ is H, R⁶ is H and R¹³ is H.

26. (previously presented) A method of claim 1 wherein the compound is a compound of Formula (110):

- a compound of Formula (110) wherein R4 is H, R5 is H and R6 is H;
- a compound of Formula (110) wherein R^4 is H, R^5 is F and R^6 is F;
- a compound of Formula (110) wherein R⁴ is H, R⁵ is F and R⁶ is H;
- a compound of Formula (110) wherein R4 is H, R5 is H and R6 is CI;
- a compound of Formula (110) wherein R^4 is H, R^5 is CI and R^6 is F;
- a compound of Formula (110) wherein R^4 is H, R^5 is F and R^6 is CI; and
- a compound of Formula (110) wherein R⁴ is H, R⁵ is OMe and R⁶ is H.

27. (Previously presented) A method of claim 1 wherein the compound is a compound of Formula (120):

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (120) wherein R^4 is H, R^5 is H and R^6 is H; a compound of Formula (120) wherein R^4 is H, R^5 is F and R^6 is F; a compound of Formula (120) wherein R^4 is H, R^5 is F and R^6 is H; a compound of Formula (120) wherein R^4 is H, R^5 is H and R^6 is H; a compound of Formula (120) wherein R^4 is H, R^5 is H0 and H1 is H1 and a compound of Formula (120) wherein H2 is H3 is H4 is H5 is H6 is H5 is H5 is H6 is H9.
- 28. (Original) A method of claim 1 wherein the compound is a compound of Formula (130):

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (130) wherein R^4 is H, R^5 is H and R^6 is H; and a compound of Formula (130) wherein R^4 is H, R^5 is Bn and R^6 is H.

 (Previously presented) A method of claim 1 wherein the compound is a compound of Formula (140):

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (140) wherein R^4 is H, R^5 is H and R^6 is H; a compound of Formula (140) wherein R^4 is H, R^5 is F and R^6 is H; a compound of Formula (140) wherein R^4 is H, R^5 is F and R^6 is F; a compound of Formula (140) wherein R^4 is H, R^5 is F1 and F2 is F3 a compound of Formula (140) wherein F3 is F3 is F4 and F5 is F5 is F5 and F6 is F5 is F5 is F6 and F7 is F8 is F9 and F9 is F9 is F9 and F9 and
- (Previously Presented) A method of claim 1 wherein the compound is a compound of Formula (150).

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (150) wherein R^4 is H, R^5 is H and R^8 is H, a compound of Formula (150) wherein R^4 is H, R^6 is F and R^5 is H; a compound of Formula (150) wherein R^4 is H, R^5 is F and R^8 is C); a compound of Formula (150) wherein R^4 is H, R^6 is Cl and R^8 is F.

a compound of Formula (150) wherein R^4 is H, R^5 is H and R^6 is CI; a compound of Formula (150) wherein R^4 is H, R^5 is OMe and R^6 is H; and a compound of Formula (150) wherein R^4 is H, R^5 is F and R^6 is F.

31. (Original) A method of claim 1 wherein the compound is a compound of Formula (160)

(160)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of.

a compound of Formula (160) wherein R4 is H, R5 is H and R8 is H

32. (Original) A method of claim 1 wherein the compound is a compound of Formula (170):

(170)

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

a compound of Formula (170) wherein R^4 is H. R^5 is H and R^6 is H; a compound of Formula (170) wherein R^4 is H. R^5 is F and R^6 is H; and a compound of Formula (170) wherein R^4 is H. R^5 is F and R^6 is F. 33. (Original) A method of claim 1 wherein the compound is a compound of Formula (180):

or a pharmaceutically acceptable salt form thereof selected from the group consisting essentially of:

- a compound of Formula (180) wherein R4 is H, R5 is H and R6 is H;
- a compound of Formula (180) wherein R4 is H, R5 is F and R6 is H; and
- a compound of Formula (180) wherein R4 is H. R5 is F and R6 is F.
- 34. (Original) A method of claim 1 wherein the compound is a compound of Formula (190):

(190)

- a compound of Formula (190) wherein R4 is H, R5 is H and R6 is H.
- 35. (Original) A method of claim 1 wherein the compound is a compound of Formula (200):

- 36. (currently amended) A method of claim 1 wherein the compound is selected from the group consisting of:
- (R)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-h]iso-quinoline;
- (S)-2-methyl-4-phenyl-1,2,3,4, 8,9-hexahydro-furo[2,3-h]isoquinoline;
- (R)-7-methyl-5-phenyl-5.6.7.8-tetrahydro-furo[3,2-g]isoquinoline;
- (S)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-glisoquinoline;
- (R)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;
- (S)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;
- (R)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2, 3-h]isoquinoline;
- (S)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;
- (R)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (S)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (R)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-hlisoquinoline;
- (S)-4-(4-chloro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]- isoquinoline;
- (R)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2-h]isoquinoline;
- (S)-8-methyl-6-phenyl-2.3.6,7.8,9-hexahydro-furo[3,2-h]isoquinoline;
- (R)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;
- (S)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (R)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h- lisoquinoline;
- (S)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (R)-2-methyl-4-phenyl2,3,4,7-tetrahydro-1H-pyrrolo[2,3-h]isoquinoline; and
- (S)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo- [2,3-h]isoquinoline; or a pharmaceutically acceptable salts of said selected compound thereof.
- 37. (currently amended) A method of claim 1 wherein the compound is selected from the group consisting of:
- (+)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-h]isoquinoline;
- (-)-2-methyl-4-phenyl-1,2,3,4,8,9-hexahydro-furo[2,3-h]isoquinoline;
- (+)-7-methyl-5-phenyl-5,6,7,8-tetrahydro-furo[3,2-g]isoquinoline;
- $(\hbox{-})\hbox{-}7\hbox{-}methyl\hbox{-}5\hbox{-}phenyl\hbox{-}5,6,7,8\hbox{-}tetrahydro-furo} \hbox{[3,2-g]} is oquino line;$

- (+)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (-)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (+)-4-(3,4-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- $(\hbox{-})\hbox{-}4\hbox{-}(3,4\hbox{-}difluoro\hbox{-}phenyl)\hbox{-}2\hbox{-}methyl\hbox{-}1,2,3,4\hbox{-}tetrahydro\hbox{-}furo[2,3\hbox{-}h]isoquinoline;}$
- (+)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (-)-2-methyl-4-phenyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- $(+)\text{-}4\text{-}(4\text{-}chloro\text{-}phenyl})\text{-}2\text{-}methyl\text{-}1,2,3,4\text{-}tetrahydrofuro}[2,3\text{-}h] is oquino line;$
- $(\hbox{--})\hbox{--}4\hbox{--}(4\hbox{--}chloro\hbox{--}phenyl)\hbox{--}2\hbox{--}methyl\hbox{--}1,2,3,4\hbox{--}tetrahydro\hbox{--}furo[2,3\hbox{--}h] is oquinoline;}$
- (+)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2h]isoquinoline;
- (-)-8-methyl-6-phenyl-2,3,6,7,8,9-hexahydro-furo[3,2-h]isoquinoline;
- (+)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (-)-4-(4-fluoro-phenyl)-2-methyl-1,2,3,4-tetrahydrofuro[2,3-h]isoquinoline;
- (+)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]i- soquinoline;
- (-)-4-(3,5-difluoro-phenyl)-2-methyl-1,2,3,4-tetrahydro-furo[2,3-h]isoquinoline;
- (+)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo[2,3-h]isoquinoline; and
- (-)-2-methyl-4-phenyl-2,3,4,7-tetrahydro-1H-pyrrolo[-2,3-h]isoquinoline; or a pharmaceutically acceptable salts of said selected compound thereof.